125 related articles for article (PubMed ID: 35156879)
1. Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia.
Okubo L; Andrick B; Rampulla R; Leri F
J Oncol Pharm Pract; 2022 Jun; 28(4):898-903. PubMed ID: 35156879
[TBL] [Abstract][Full Text] [Related]
2. Impact of a cefepime shortage on dosing regimens and outcomes in hospitalized adults with febrile neutropenia.
Haiduc M; Patel M; Walsh TL; Moffa MA; Bremmer DN
J Oncol Pharm Pract; 2021 Mar; 27(2):297-304. PubMed ID: 32316878
[TBL] [Abstract][Full Text] [Related]
3. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
[TBL] [Abstract][Full Text] [Related]
4. Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia.
Crawford R; Perkins NB; Hobbs DA; Hobbs ALV
Pharmacotherapy; 2022 Oct; 42(10):798-805. PubMed ID: 36106434
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.
Mustafa MM; Carlson L; Tkaczewski I; McCracken GH; Buchanan GR
Pediatr Infect Dis J; 2001 Mar; 20(3):362-9. PubMed ID: 11303851
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
[TBL] [Abstract][Full Text] [Related]
8. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
[TBL] [Abstract][Full Text] [Related]
9. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
Aamir M; Abrol P; Sharma D; Punia H
Trop Doct; 2016 Jul; 46(3):142-8. PubMed ID: 26612093
[TBL] [Abstract][Full Text] [Related]
10. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
12. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.
Chuang YY; Hung IJ; Yang CP; Jaing TH; Lin TY; Huang YC
Pediatr Infect Dis J; 2002 Mar; 21(3):203-9. PubMed ID: 12005083
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
Fujita M; Matsumoto T; Inoue Y; Wataya H; Takayama K; Ishida M; Ebi N; Kishimoto J; Ichinose Y;
J Infect Chemother; 2016 Apr; 22(4):235-9. PubMed ID: 26867793
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.
Erman M; Akova M; Akan H; Korten V; Ferhanoğlu B; Köksal I; Cetinkaya Y; Uzun O; Unal S;
Scand J Infect Dis; 2001; 33(11):827-31. PubMed ID: 11760163
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH
Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925
[TBL] [Abstract][Full Text] [Related]
16. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
[TBL] [Abstract][Full Text] [Related]
17. Low utilization of vancomycin in febrile neutropenia: real-world evidence from 4 Brazilian centers.
Ramos JF; Pereira AD; Seiwald MCN; Gandolpho LS; Molla VC; Guaraná M; Nouér SA; Nucci M; Rodrigues CA
Support Care Cancer; 2023 Nov; 31(12):687. PubMed ID: 37947888
[TBL] [Abstract][Full Text] [Related]
18. Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia.
Vicente M; Al-Nahedh M; Parsad S; Knoebel RW; Pisano J; Pettit NN
J Oncol Pharm Pract; 2017 Dec; 23(8):575-581. PubMed ID: 27609336
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
[TBL] [Abstract][Full Text] [Related]
20. Cefepime monotherapy for febrile neutropenia in patients with lung cancer.
Saito H; Takahashi K; Okuno M; Saka H; Imaizumi K; Hasegawa Y; Tanikawa Y; Yamamoto M; Taniguchi H; Shindoh J; Suzuki R; Shimokata K;
J Infect Chemother; 2014 Jun; 20(6):365-9. PubMed ID: 24679653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
